[CAS NO. 1803176-05-7] Oleclumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1803176-05-7]

Catalog

HY-P99039

Brand

MCE

CAS

1803176-05-7

DESCRIPTION [1803176-05-7]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Oleclumab]

For research use only. We do not sell to patients.

Summary

Oleclumab (MEDI9447) is a human IgG1λ anti- CD73 monoclonal antibody that inhibits CD73 function. Oleclumab has an anti-tumor activity ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04261075	MedImmune LLC	Advanced Solid Tumors	March 3, 2020	Phase 1
NCT03616886	Jules Bordet Institute\|AstraZeneca	Triple Negative Breast Cancer	December 28, 2018	Phase 1\|Phase 2
NCT03819465	AstraZeneca	Metastatic Non-Small Cell Lung Cancer (NSCLC)	December 27, 2018	Phase 1
NCT03742102	AstraZeneca	Triple Negative Breast Neoplasms	December 21, 2018	Phase 1\|Phase 2
NCT04668300	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Metastatic Angiosarcoma\|Metastatic Dedifferentiated Liposarcoma\|Metastatic Osteosarcoma\|Recurrent Angiosarcoma\|Recurrent Dedifferentiated Liposarcoma\|Recurrent Osteosarcoma\|Refractory Dedifferentiated Liposarcoma\|Refractory Osteosarcoma	November 26, 2020	Phase 2
NCT03875573	Jules Bordet Institute\|Institut Curie\|AstraZeneca	Luminal B	November 6, 2019	Phase 2
NCT04262375	University Health Network, Toronto\|AstraZeneca	Non Small Cell Lung Cancer\|Renal Cell Carcinoma	January 2021	Phase 2
NCT04940286	M.D. Anderson Cancer Center	Borderline Resectable Pancreatic Adenocarcinoma\|Resectable Pancreatic Adenocarcinoma\|Stage IA Pancreatic Cancer AJCC v8\|Stage IB Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8	September 28, 2021	Phase 2
NCT02503774	MedImmune LLC	Solid Tumors	July 24, 2015	Phase 1
NCT03833440	Assistance Publique Hopitaux De Marseille	Non-small Cell Lung Cancer	October 8, 2019	Phase 2
NCT03381274	MedImmune LLC	Carcinoma, Non-Small-Cell Lung	May 8, 2018	Phase 1\|Phase 2
NCT03736473	AstraZeneca	Advanced Solid Malignancies	November 7, 2018	Phase 1
NCT05061550	AstraZeneca\|Parexel	Non-small Cell Lung Cancer	April 14, 2022	Phase 2
NCT04262388	University Health Network, Toronto\|AstraZeneca	Pancreatic Ductal Adenocarcinoma\|Non-small Cell Lung Cancer\|Squamous Cell Carcinoma of Head and Neck	January 2021	Phase 2
NCT05221840	AstraZeneca	Non-Small Cell Lung Cancer	February 7, 2022	Phase 3
NCT04145193	MedImmune LLC	Microsatellite-stable Colorectal Cancer	October 1, 2020	Phase 2
NCT03794544	MedImmune LLC	Resectable\|Early-stage\|NSCLC	March 8, 2019	Phase 2
NCT04089553	AstraZeneca	Prostate Cancer\|Metastatic Castration-Resistant Prostate Cancer (mCRPC)	August 29, 2019	Phase 2
NCT03611556	MedImmune LLC	Carcinoma\|Metastatic Pancreatic Adenocarcinoma	June 21, 2018	Phase 1\|Phase 2
NCT03822351	MedImmune LLC	Stage III Non-small Cell Lung Cancer\|Unresectable	December 19, 2018	Phase 2
NCT02740985	AstraZeneca	Advanced Solid Malignancies\|Non-Small Cell Lung Cancer (NSCLC)\|Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)\|Colorectal Carcinoma (CRC)	June 17, 2016	Phase 1
NCT03773666	Dana-Farber Cancer Institute\|AstraZeneca	Muscle Invasive Bladder Cancer	February 20, 2019	Phase 1
NCT03334617	AstraZeneca	Non-Small Cell Lung Cancer	December 18, 2017	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Roy S Herbst, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 22;JCO2200227.